CAM-4628

CAM-4628 is a preclinical-stage small molecule inhibitor of Transglutaminase 2 (TG2) being developed by Isterian Biotech, a subsidiary of Cambrian Bio. The drug is primarily targeted at treating Idiopathic Pulmonary Fibrosis (IPF) by modulating the TGF-β signaling pathway. TG2 is an enzyme that cross-links extracellular matrix proteins and facilitates the activation of latent TGF-β, a potent pro-fibrotic cytokine. By inhibiting TG2, CAM-4628 aims to reduce the stabilization of the fibrotic matrix and decrease TGF-β-mediated fibrotic signaling, potentially offering a novel therapeutic approach for patients with progressive lung fibrosis.